Evolus, a company dedicated to aesthetic medicine that is currently developing its own botulinum toxin injectable, has expanded its leadership team with the appointments of three key executives, who will report to President and CEO David Moatazedi. Kurt Knab is the vice president of sales, Alejandro “Alex” Sabad is vice president of operations and Amy Marinne Fox is vice president of human resources.
Knab joins Evolus from Medline Industries where he served as VP of business development and sales. Prior to that, he spent sixteen years at LifeCell Corporation where he held various roles in sales leadership and ultimately served as VP of U.S. sales.
Sabad brings more than 25 years of combined industry and consulting experience with a range of life science companies. He formerly served as a managing director at Deloitte Consulting. Prior to Deloitte, he served as VP of operations strategy and network performance management at MedImmune, AstraZeneca’s global biologics division.
Fox has more than 20 years of experience. She previously served as vice president of human resources at Orexigen Therapeutics. Prior to Orexigen, she served as director of human resources at Synteract, a global clincal research organization specializing in the delivery of clinical trial solutions across multiple therapeutic areas.
“Evolus continues to attract accomplished talent in the industry, and we are pleased to announce the addition of these seasoned leaders to our team,” said Moatazedi. “Their exceptional backgrounds and industry knowledge complete our leadership team as we rapidly advance towards anticipated FDA approval in February 2019 and expected commercial launch in Spring 2019.”